Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief...
MISSISSAUGA, Ontario, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its...
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and...
- Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in...
-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of...
STOCKHOLM, SWEDEN / ACCESSWIRE / November 9, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced...
Revenue recognised for 2023 expected to be up 120% at c. £2.2 million with sales secured in 2023 expected to...
ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIESANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to...
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg PharmaPoolbeg team boosted by highly experienced executives with track...
Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / November...
Adding to Medidata’s already extensive platform, Medidata Clinical Data Studio and Medidata Health Record Connect usher in a new era...
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced...
Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal...
Click here to register for November 14 investor webcastCompany plans to file its Earnings Report on November 14, 2023 on...
People living with treatment-resistant active psoriatic arthritis reported meaningful improvements in pain, physical function and fatigue on guselkumab through six...
Company developing innovative two-fold technology designed to both detect the neural signals relating to pain or disease and ablate them...
CARMEL, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Clariti to be PharmAla’s exclusive Long-Term Strategic Advisory and Investment Banking PartnerVANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) --...
Award reflects company’s ongoing commitment to advancing women in leadership and maintaining a gender-equitable cultureDURHAM, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE)...